Rosiglitazone drives cavin-2/SDPR expression in adipocytes in a CEBPa-dependent manner

Hansson B, etc
PLoS ONE, 2017

Caveolae are abundant adipocyte surface domains involved in insulin signaling, membrane trafficking and lipid homeostasis. Transcriptional control mechanisms for caveolins and cavins, the building blocks of caveolae, are thus arguably important for adipocyte biology and studies in this area may give insight into insulin resistance and diabetes. Here we addressed the hypothesis that one of the less characterized caveolar components, cavin-2 (SDPR), is controlled by CCAAT/Enhancer Binding Protein (CEBPa) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG). Using human mRNA expression data we found that SDPR correlated with PPARG in several tissues. This was also observed during differentiation of 3T3-L1 fibroblasts into adipocytes. Treatment of 3T3-L1-derived adipocytes with the PPAR¿-activator Rosiglitazone increased SDPR and CEBPa expression at both the mRNA and protein levels. Silencing of CEBPa antagonized these effects. Further, adenoviral expression of PPAR¿/CEBPa or Rosiglitazone-treatment increased SDPR expression in primary rat adipocytes. The myocardin family coactivator MKL1 was recently shown to regulate SDPR expression in human coronary artery smooth muscle cells. However, we found that actin depolymerization, known to inhibit MKL1 and MKL2, was without effect on SDPR mRNA levels in adipocytes, even though overexpression of MKL1 and MKL2 had the capacity to increase caveolins and cavins and to repress PPAR¿/CEBPa. Altogether, this work demonstrates that CEBPa expression and PPAR¿-activity promote SDPR transcription and further supports the emerging notion that PPAR¿/CEBPa and MKL1/MKL2 are antagonistic in adipocytes.

Read more »

doi: 10.1371/journal.pone.0173412
Lund University,